antipsychotics also known class psychotropic medication primarily used manage psychosis including delusions hallucinations paranoia disordered thought principally schizophrenia also range psychotic also mainstay together mood stabilizers treatment bipolar prior research shown use antipsychotic associated smaller brain tissue including white matter brain shrinkage dose dependent time recent controlled trial suggests second generation combined intensive psychosocial may potentially prevent pallidal brain volume loss first episode use antipsychotics may result many unwanted side effects involuntary movement disorders gynecomastia impotence weight gain metabolic syndrome longterm use produce adverse effects tardive dyskinesia tardive dystonia tardive akathisia prevention adverse effects possible concomitant medication strategies including use betablockers currently treatments tardive diseases well established firstgeneration antipsychotics eg chlorpromazine known typical antipsychotics first introduced others developed early secondgeneration antipsychotics known atypical antipsychotics introduced firstly clozapine early followed others eg generations medication block receptors brain dopamine atypicals tend act serotonin receptors well neuroleptic originating greek νεῦρον neuron λαμβάνω take hold meaning takes common neurological effects side antipsychotics frequently used following conditions antipsychotics generally recommended treating behavioral problems associated dementia given risk use tends greater potential said insomnia recommended firstline evidencebased indications using antipsychotics children eg tic disorder bipolar disorder psychosis use antipsychotics outside contexts eg treat behavioral problems warrants significant antipsychotics used treat tics associated tourette aripiprazole atypical antipsychotic used addon medication ameliorate sexual dysfunction symptom selective serotonin reuptake inhibitor antidepressants quetiapine used treat generalized anxiety antipsychotic drug treatment key component schizophrenia treatment recommendations national institute health care excellence american psychiatric british society main aim treatment antipsychotics reduce positive symptoms psychosis include delusions mixed evidence support significant impact antipsychotic use primary negative symptoms apathy lack emotional affect lack interest social interactions cognitive symptoms memory impairments reduced ability plan execute general efficacy antipsychotic treatment reducing positive symptoms appears increase severity baseline antipsychotic medications work relatively way antagonizing dopamine receptors however differences comes typical atypical antipsychotics example atypical antipsychotic medications seen lower neurocognitive impairment associated schizophrenia conventional antipsychotics although reasoning mechanics still unclear applications antipsychotic drugs treatment schizophrenia include prophylaxis showing symptoms suggest high risk developing psychosis treatment firstepisode psychosis maintenance therapy form prophylaxis maintenance therapy aims maintain therapeutic benefit prevent symptom relapse treatment recurrent episodes acute test batteries pace personal assessment crisis evaluation clinic cops criteria prodromal syndromes measure lowlevel psychotic symptoms cognitive disturbances used evaluate people early lowlevel symptoms psychosis test results combined family history information identify patients highrisk group considered risk progression frank psychosis within two patients often treated low doses antipsychotic drugs goal reducing symptoms preventing progression frank psychosis generally useful reducing symptoms clinical trials date show little evidence early use antipsychotics improves longterm outcomes prodromal symptoms either alone combination cognitivebehavioral firstepisode psychosis fep first time psychotic symptoms presented nice recommends people presenting firstepisode psychosis treated antipsychotic drug cognitive behavioral therapy cbt nice recommends expressing preference cbt alone informed combination treatment diagnosis schizophrenia made time takes longer determined around presenting first episode psychosis later diagnosed conversion rate first episode drug induced psychosis bipolar disorder schizophrenia lower people converting either bipolar disorder nice makes distinction substanceinduced psychosis form psychosis rate conversion differs different classes pharmacological options specific treatment fep discussed recent goals treatment fep include reducing symptoms potentially improving longterm treatment outcomes randomized clinical trials provided evidence efficacy antipsychotic drugs achieving former goal firstgeneration second generation antipsychotics showing equal efficacy evidence early treatment favorable effect longterm outcomes placebocontrolled trials first secondgeneration antipsychotic drugs consistently demonstrate superiority active drugs placebos suppressing psychotic large metaanalysis trials antipsychotic drugs schizophrenia acute psychotic episodes showed effect size little difference efficacy among approved antipsychotic drugs including first secondgeneration efficacy drugs suboptimal patients achieve complete resolution symptoms response rates calculated using various cutoff values symptom reduction low interpretation complicated high placebo response rates selective publication clinical trial majority patients treated antipsychotic drug experience response within four weeks goals continuing treatment maintain suppression symptoms prevent relapse improve quality life support engagement psychosocial maintenance therapy antipsychotic drugs clearly superior placebo preventing relapse associated weight gain movement disorders high dropout trial following persons receiving maintenance therapy acute psychotic episode found obtained longlasting symptom reduction achieved remission experienced satisfactory quality life effect relapse prevention long term outcomes uncertain historical studies show little difference long term outcomes introduction antipsychotic maintenance therapy clearly reduces rate relapses requiring hospitalization large observational study finland found people eventually discontinued antipsychotics risk hospitalized mental health problem dying increased longer dispensed presumably took antipsychotics prior stopping therapy people stop taking antipsychotics remained low risk relapse hospitalization compared authors speculated difference may people discontinued treatment longer time severe mental illness discontinued antipsychotic therapy significant challenge use antipsychotic drugs prevention relapse poor rate spite relatively high rates adverse effects associated drugs evidence including higher dropout rates placebo arms compared treatment arms randomized clinical trials suggests patients discontinue treatment suboptimal someone experiences psychotic symptoms due nonadherence may compelled receive treatment process called involuntary commitment forced accept treatment including antipsychotics person also committed treatment outside hospital called outpatient commitment antipsychotics longacting injectable lai depot form suggested method decreasing medication nonadherence sometimes also called nice advises lais offered patients preventing covert intentional nonadherence clinical lais used ensure adherence outpatient metaanalysis found lais resulted lower rates rehospitalization hazard ratio however results statistically significant confidence interval antipsychotics routinely used often conjunction mood stabilisers lithiumvalproate firstline treatment manic mixed episodes associated bipolar reason combination therapeutic delay aforementioned mood stabilisers valproate therapeutic effects usually seen around five days treatment commenced whereas lithium usually takes least full therapeutic effects seen comparatively rapid antimanic effects antipsychotic antipsychotics documented efficacy used alone acute maniamixed least five atypical antipsychotics also found possess efficacy treatment bipolar depression monotherapy whereas proven effective broadspectrum ie three types mixed depressive prophylactic maintenance treatments patients bipolar disorder recent cochrane review also found olanzapine less favourable riskbenefit ratio lithium maintenance treatment bipolar american psychiatric association uk national institute health care excellence recommend antipsychotics managing acute psychotic episodes schizophrenia bipolar disorder longerterm maintenance treatment reducing likelihood state response given antipsychotic variable trials may necessary lower doses preferred possible number studies looked levels compliance adherence antipsychotic regimes found discontinuation stopping taking patients associated higher rates relapse including hospitalization psychosis agitation develop many percent people living nursing despite lack fda approval blackbox warnings atypical antipsychotics often prescribed people assessment underlying cause behavior needed prescribing antipsychotic medication symptoms antipsychotics old age dementia showed modest benefit compared placebo managing aggression psychosis combined fairly large increase serious adverse events thus antipsychotics used routinely treat dementia aggression psychosis may option cases severe distress risk physical harm psychosocial interventions may reduce need fda issued advisory warning increased risk death atypical antipsychotics used subsequent years use atypical antipsychotics treat dementia decreased nearly number atypical antipsychotics benefits used addition treatments major depressive aripiprazole quetiapine extendedrelease olanzapine used conjunction fluoxetine received food drug administration fda labelling however greater risk side effects use compared using traditional greater risk serious side effects antipsychotics eg quetiapine denied approval monotherapy major depressive disorder generalized anxiety disorder instead approved adjunctive treatment combination traditional recent study use antipychotics unipolar depression concluded use drugs addition antidepressants alone leads worse disease outcome effect especially pronounced younger patients psychotic unipolar depression considering wide use combination therapies studies side effects antipychotics addon therapy besides uses antipsychotics may used disorder posttraumatic stress disorder personality disorders tourette syndrome autism agitation evidence however support use atypical antipsychotics eating disorders personality atypical antipsychotic risperidone may useful use low doses antipsychotics insomnia common recommended little evidence benefit well concern regarding adverse serious adverse effects may also occur low doses used dyslipidemia recent network metaanalysis doubleblind randomized controlled trials drug therapies vs placebo insomnia adults found quetiapine demonstrated shortterm benefits sleep low dose antipsychotics may also used treatment impulsebehavioural cognitiveperceptual symptoms borderline personality despite lack evidence supporting benefit antipsychotics people personality disorders serious mental illness prescribed uk primary care many people receive medication year contrary nice children may used disruptive behavior disorders mood disorders pervasive developmental disorders intellectual antipsychotics weakly recommended tourette syndrome although effective side effects situation similar autism much evidence offlabel use antipsychotics example dementia ocd ptsd personality disorders tourettes insufficient scientific quality support use especially strong evidence increased risks stroke tremors significant weight gain sedation gastrointestinal uk review unlicensed usage children adolescents reported similar mixture findings survey children pervasive developmental disorder found taking antipsychotic drug commonly irritability aggression agitation risperidone aripiprazole approved us fda treatment irritability autistic children review uk found use antipsychotics england doubled children prescribed antipsychotics conditions approval aggressive challenging behavior adults intellectual disability often treated antipsychotic drugs despite lack evidence base recent randomized controlled trial however found benefit placebo recommended use antipsychotics way longer regarded acceptable routine antipsychotics may option together stimulants people adhd aggressive behavior treatments found useful prevention delirium among admitted unclear whether atypical secondgeneration antipsychotics offer advantages older first generation amisulpride olanzapine risperidone clozapine may effective associated greater side typical antipsychotics equal dropout symptom relapse rates atypicals used low moderate clozapine effective treatment respond poorly drugs treatmentresistant refractory potentially serious side effect agranulocytosis lowered white blood cell count less due bias research accuracy comparisons atypical antipsychotics us government body national institute mental health published results major independent study catie atypical studied risperidone quetiapine ziprasidone better typical perphenazine measures used produce fewer adverse effects typical antipsychotic perphenazine although patients discontinued perphenazine owing extrapyramidal effects compared atypical agents vs atypical antipsychotics appear lead improved rates medication adherence compared typical many researchers question firstline prescribing atypicals typicals even question distinction two contrast researchers point significantly higher risk tardive dyskinesia extrapyramidal symptoms typicals reason alone recommend firstline treatment atypicals notwithstanding greater propensity metabolic adverse effects uk government organization nice recently revised recommendation favoring atypicals advise choice individual one based particular profiles individual drug patients preferences reevaluation evidence necessarily slowed bias toward prescribing generally one antipsychotic drug used time increased adverse atypicals associated considerable weight gain diabetes risk metabolic unwanted side effects cause people stop treatment resulting risperidone atypical similar rate extrapyramidal symptoms haloperidol rare potentially lethal condition neuroleptic malignant syndrome nms associated use antipsychotics early recognition timely intervention rates declined however awareness syndrome advised enable another less rare condition tardive dyskinesia occur due longterm use antipsychotics developing months years use often reported use typical rarely antipsychotics may cause tardive clozapine associated side effects include weight gain tiredness hypersalivation serious adverse effects include seizures nms neutropenia agranulocytosis lowered white blood cell count use needs careful clozapine also associated thromboembolism including pulmonary embolism myocarditis systematic review clozapineassociated pulmonary embolism indicates adverse effect often fatal early onset dosedependent findings advised consideration using prevention therapy venous thromboembolism starting treatment clozapine continuing six constipation three times likely occur use clozapine severe cases lead ileus bowel ischemia resulting many rare clozapine adverse effects include periorbital edema due several possible mechanisms eg inhibition plateletderived growth factor receptors leading increased vascular permeability antagonism renal dopamine receptors electrolyte fluid imbalance immunemediated hypersensitivity however risk serious adverse effects clozapine low beneficial effects gained reduced risk suicide typical antipsychotics atypical risperidone side effect sexual clozapine olanzapine quetiapine associated beneficial effects sexual functioning helped various common incidence antipsychotic drugs adverse effects antipsychotics rareuncommon incidence antipsychotic drugs adverse effects antipsychotics include studies found decreased life expectancy associated use antipsychotics argued studies antipsychotics may also increase risk early death individuals antipsychotics typically worsen symptoms people depersonalisation antipsychotic polypharmacy prescribing two antipsychotics time individual common practice evidencebased recommended initiatives curtail similarly use excessively high doses often result polypharmacy continues despite clinical guidelines evidence indicating usually effective usually metaanalysis observational studies two million individuals suggested moderate association antipsychotic use breast loss grey matter brain structural changes time observed amongst people diagnosed schizophrenia metaanalyses effects antipsychotic treatment grey matter volume brains structure reached conflicting conclusions metaanalysis concluded grey matter loss greater patients treated first generation antipsychotics relative treated atypicals hypothesized protective effect atypicals one possible second metaanalysis suggested treatment antipsychotics associated increased grey matter animal studies found monkeys exposed first secondgeneration antipsychotics experience significant reduction brain volume resulting reduction brain volume month national association state mental health program directors said antipsychotics interchangeable recommend including trying least one weightneutral treatment patients potential metabolic subtle longlasting forms akathisia often overlooked confused postpsychotic depression particular lack extrapyramidal aspect psychiatrists taught expect looking signs adverse effect cognitive increased risk death people dementia along worsening symptoms described british national formulary recommends gradual withdrawal discontinuing antipsychotics avoid acute withdrawal syndrome rapid symptoms withdrawal commonly include nausea vomiting loss symptoms may include restlessness increased sweating trouble less commonly may feeling world spinning numbness muscle symptoms generally resolve short period tentative evidence discontinuation antipsychotics result may also result recurrence condition rarely tardive dyskinesia occur medication unexpected psychotic episodes observed patients withdrawing clozapine referred supersensitivity psychosis equated tardive tardive dyskinesia may abate withdrawal antipsychotic agent may withdrawal effects may also occur switching person one antipsychotic another presumed due variations potency receptor activity withdrawal effects include cholinergic rebound activation syndrome motor syndromes including dyskinesias adverse effects likely rapid changes antipsychotic agents making gradual change antipsychotics minimises withdrawal british national formulary recommends gradual withdrawal discontinuing antipsychotic treatment avoid acute withdrawal syndrome rapid process crosstitration involves gradually increasing dose new medication gradually decreasing dose old medication city hackney clinical commissioning group found patients area july regular medication reviews health checks registered serious mental illness average taking drugs six years typical practice england patients probably clinically used antipsychotic medications listed drug group trade names appear parentheses review stated division antipsychotics first second generation perhaps notes indicates drugs longer never marketed englishspeaking countries denotes drugs longer never begin marketed united states antipsychotics firmly placed either firstgeneration secondgeneration classes denotes drugs withdrawn worldwide category drugs called first secondgeneration depending literature used third generation antipsychotics recognized demonstrating receptor agonism opposed receptor antagonistic mechanism firstgeneration typical secondgeneration atypical antipsychotic antipsychotic drugs haloperidol chlorpromazine tend block dopamine receptors dopaminergic pathways brain means dopamine released pathways less effect excess release dopamine mesolimbic pathway linked psychotic experiences decreased dopamine release prefrontal cortex excess dopamine release pathways associated psychotic episodes schizophrenia bipolar addition antagonistic effects dopamine antipsychotics particular atypical neuroleptics also antagonize receptors different alleles receptor associated schizophrenia psychoses including higher concentrations receptors cortical subcortical areas particular right caudate nucleus historically typical antipsychotics particularly selective also block dopamine receptors mesocortical pathway tuberoinfundibular pathway nigrostriatal pathway blocking receptors pathways thought produce unwanted side effects typical antipsychotics produce see commonly classified spectrum low potency high potency potency referred ability drug bind dopamine receptors effectiveness drug highpotency antipsychotics haloperidol general doses milligrams cause less sleepiness calming effects lowpotency antipsychotics chlorpromazine thioridazine dosages several hundred milligrams latter greater degree anticholinergic antihistaminergic activity counteract dopaminerelated atypical antipsychotic drugs similar blocking effect receptors however also act serotonin receptors especially receptors clozapine quetiapine appear bind long enough elicit antipsychotic effects long enough induce extrapyramidal side effects prolactin antagonism increases dopaminergic activity nigrostriatal pathway leading lowered extrapyramidal side effect liability among atypical ability antipsychotics antagonize serotonin pathways enabling sensitisation postsynaptic serotonin receptors mdma exposure intense excitatory receptors activate effect observed antagonizing normal amphetamine hypothetical fact antipsychotics sensitize exact postsynaptic receptors flooded respective neurotransmitter serotonine dopamine amphetamine ci ors cis note notable mean sideeffects particularly unique antipsychotic drug question example clozapine notorious ability cause agranulocytosis data propensity particular drug cause particular ae unavailable estimation substituted based pharmacologic profile drug acronyms used legend acronyms used original antipsychotic drugs happened upon largely chance tested effectiveness first chlorpromazine developed surgical anesthetic first used psychiatric patients powerful calming effect time regarded nonpermanent pharmacological lobotomy time used treat many behavioral disorders including psychosis although effect markedly reduce behavior mental functioning types however chlorpromazine proved reduce effects psychosis effective specific manner lobotomy even though known capable causing severe sedation underlying neurochemistry involved since studied detail subsequent antipsychotic drugs developed rational drug design discovery chlorpromazines psychoactive effects led research resulted development antidepressants anxiolytics majority drugs used management psychiatric conditions henri laborit described chlorpromazine inducing indifference towards happening around nonpsychotic nonmanic patients jean delay pierre deniker described controlling manic psychotic agitation former claimed discovered treatment agitation anyone latter team claimed discovered treatment psychotic considerable debate within psychiatry appropriate term use describe new late widely used term neuroleptic followed major tranquilizer first recorded use term tranquilizer dates early nineteenth frederik f yonkman chemist swissbased cibapharmaceutical company first used term tranquilizer differentiate reserpine older word neuroleptic coined delay deniker discovery antipsychotic effects derived greek νεῦρον neuron originally meaning sinew today referring nerves λαμβάνω lambanō meaning take hold thus word means taking hold ones nerves often taken refer also common side effects reduced activity general well lethargy impaired motor control although effects unpleasant cases harmful one time along akathisia considered reliable sign drug term ataraxy coined neurologist howard fabing classicist alister cameron describe observed effect psychic indifference detachment patients treated term derived greek adjective ἀτάρακτος ataraktos means disturbed excited without confusion steady use terms tranquilizer ataractic medical practitioners distinguished major tranquilizers major ataractics referred drugs used treat psychoses minor tranquilizers minor ataractics referred drugs used treat popular terms infrequently used today abandoned favor antipsychotic refers drugs desired today minor tranquilizer refer anxiolytic andor hypnotic drugs benzodiazepines nonbenzodiazepines useful generally shortterm management insomnia together cognitive behavioral therapy potentially addictive sedatives antipsychotics broadly divided two groups typical firstgeneration antipsychotics atypical secondgeneration antipsychotics difference first secondgeneration antipsychotics subject debate secondgeneration antipsychotics generally distinguishable presence receptor antagonism corresponding lower propensity extrapyramidal side effects compared firstgeneration term major tranquilizer used older antipsychotic drugs term neuroleptic often used synonym antipsychotic even though strictly speaking two terms interchangeable antipsychotic drugs subgroup neuroleptic drugs latter wider range antipsychotics type psychoactive psychotropic antipsychotics among biggest selling profitable drugs generating billion global sales us estimated million patients received antipsychotics worth estimated billion prescriptions newer expensive atypicals costing average per year compared older sales us reached billion biggest selling drugs us therapeutic five years since july number antipsychotic medicines dispensed community united kingdom increased also substantial price rises risperidone mg tablets largest increased july june nhs spending additional million annually antipsychotics haloperidol microgram tablets constituted million antipsychotics nursing home population often overprescribed often purposes making easier handle dementia patients federal efforts reduce use antipsychotics us nursing homes led nationwide decrease usage antipsychotics sometimes administered part compulsory psychiatric treatment via inpatient hospital commitment outpatient commitment may administered orally cases longacting depot injections administered dorsgluteal ventrogluteal deltoid muscle shortacting parenteral formulations also exist generally reserved emergencies oral administration otherwise impossible oral formulations include immediate release extended release orally disintegrating products sublingual help ensure medications swallowed instead cheeked sublingual products eg asenapine also exist must held tongue absorption first transdermal formulation antipsychotic transdermal asenapine marketed secuado fdaapproved certain secondgeneration antipsychotics misused abused sedative tranquilizing paradoxically hallucinogenic commonly secondgeneration antipsychotic implicated case reports quetiapine abused doses taken mouth drug available manufacturer also crushed insufflated mixed water injection olanzapine another sedating secondgeneration antipsychotic also misused similar standard treatment antipsychotic abuse though switching secondgeneration antipsychotic less abuse potential eg aripiprazole joanna moncrieff argued antipsychotic drug treatment often undertaken means control rather treat specific symptoms experienced use class drugs history criticism residential care drugs used make patients calmer compliant critics claim drugs overused outside doctors feel pressure care home official review commissioned uk government ministers reported needless use antipsychotic medication dementia care widespread linked deaths per us government initiated legal action pharmaceutical company johnson johnson allegedly paying kickbacks omnicare promote antipsychotic risperidone risperdal nursing also controversy role pharmaceutical companies marketing promoting antipsychotics including allegations downplaying covering adverse effects expanding number conditions illegally promoting offlabel usage influencing drug trials publication try show expensive profitable newer atypicals superior older cheaper typicals patent following charges illegal marketing settlements two large pharmaceutical companies us set records largest criminal fines ever imposed one case involved eli lilly companys antipsychotic zyprexa involved bextra bextra case government also charged pfizer illegally marketing another antipsychotic addition astrazeneca faces numerous personalinjury lawsuits former users seroquel quetiapine amidst federalclarification needed investigations marketing expanding conditions indicated astrazenecas seroquel eli lillys zyprexa become biggest selling antipsychotics global sales billion billion harvard university medical professor joseph biederman conducted research bipolar disorder children led increase diagnoses senatewhich investigation found biederman also received million speaking consulting fees undisclosed harvard companies including makers antipsychotic drugs prescribed children bipolar disorder johnson johnson gave research center headed biederman research conducted part risperdal companys antipsychotic drug biederman responded saying money influence promote specific diagnosis pharmaceutical companies also accused attempting set mental health agenda activities funding consumer advocacy recommended persons dementia exhibit behavioral psychological symptoms given antipsychotics trying update taking antipsychotics population increased risk cerebrovascular effects parkinsonism extrapyramidal symptoms sedation confusion cognitive adverse effects weight gain increased physicians caretakers persons dementia try address symptoms including agitation aggression apathy anxiety depression irritability psychosis alternative treatments whenever antipsychotic use replaced elderly persons often dementia treated first antipsychotics best management httpsenwikipediaorgwikiantipsychotic